For VEGFR2/KDR rs11133360 C/T, TT carriers had improved OS (HR = 0.63, 95% CI: 0.40–0.99, p-val = 0.045) in APD, partially in line with our earlier study that any T at this locus was associated with improved PFS in mCRC, renal cell carcinoma and breast cancer patients treated with BVZ (6,7,22 and references therein). This evidence concerns the gene KDR and hereditary clear cell renal cell carcinoma.